← Leaderboards
Rana Rais
Johns Hopkins University
$2,718,642
Attributed
$6,459,078
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,459,078 · 4
By mechanism
R01$5,728,504 · 3
P30$730,574 · 1
Top collaborators
- Barbara Stauch Slusher9 shared
- Kannan Rangaramanujam5 shared
- Takashi Tsukamoto3 shared
- Robert H Blelloch2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Hugo W Moser$5,176,943
- Gerald V Raymond$6,168,992
- Barbara Stauch Slusher$18,499,514
- Peter R Rapp$7,647,958
- Michela Gallagher$29,291,902
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposEnzymesOralDrug KineticsExhibitsSphingomyelinaseSphingomyelinsDosePlayPlasmaBrainDrug DiscoveryIn VitroCeramidesCognitionIn VivoClinical TranslationBiogenesisMouse ModelAnalogPharmaceutical PreparationsGeneticHigh Throughput ScreeningEfficacy Testing
Grant awards (12)
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$710,695
R01 · FY2025 · AG
Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers$680,034
R01 · FY2025 · CA
Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers$695,916
R01 · FY2024 · CA
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$683,930
R01 · FY2024 · AG
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$471,402
R01 · FY2024 · AG · contact PI
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$651,180
R01 · FY2023 · AG
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$471,402
R01 · FY2023 · AG · contact PI
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$526,162
R01 · FY2022 · AG · contact PI
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$458,867
R01 · FY2021 · AG · contact PI
Therapeutic Core$359,760
P30 · FY2021 · MH · contact PI
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$378,916
R01 · FY2020 · AG · contact PI
Therapeutic Core$370,814
P30 · FY2020 · MH · contact PI